(HSIC) Henry Schein - Ratings and Ratios
Dental, Medical, Pharmaceuticals, Equipment, Software
HSIC EPS (Earnings per Share)
HSIC Revenue
Description: HSIC Henry Schein
Henry Schein Inc is a global healthcare distributor and provider of value-added services to dental and medical practitioners. The companys diversified portfolio includes dental and medical equipment, consumables, and pharmaceuticals, as well as financial services, software solutions, and practice management tools. With a presence in multiple markets worldwide, HSIC serves a broad customer base, including dental and medical practices, laboratories, and institutional healthcare providers.
From a business perspective, HSICs strength lies in its ability to provide a one-stop-shop for healthcare professionals, offering a wide range of products and services that cater to their diverse needs. The companys global distribution network and logistics capabilities enable it to efficiently supply products to customers, while its value-added services, such as practice management software and financial services, help providers streamline their operations and improve patient care.
Analyzing the
Based on the
Additional Sources for HSIC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HSIC Stock Overview
Market Cap in USD | 9,132m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception | 1995-11-03 |
HSIC Stock Ratings
Growth Rating | 10.9 |
Fundamental | 19.2 |
Dividend Rating | 0.0 |
Rel. Strength | 19.1 |
Analysts | 3.5 of 5 |
Fair Price Momentum | 68.62 USD |
Fair Price DCF | 86.82 USD |
HSIC Dividends
Currently no dividends paidHSIC Growth Ratios
Growth Correlation 3m | 82.2% |
Growth Correlation 12m | 12.3% |
Growth Correlation 5y | -0.5% |
CAGR 5y | 4.59% |
CAGR/Max DD 5y | 0.14 |
Sharpe Ratio 12m | 0.28 |
Alpha | 5.85 |
Beta | 0.341 |
Volatility | 23.03% |
Current Volume | 1459.1k |
Average Volume 20d | 1463.2k |
As of July 03, 2025, the stock is trading at USD 74.48 with a total of 1,459,097 shares traded.
Over the past week, the price has changed by +2.32%, over one month by +7.07%, over three months by +7.55% and over the past year by +13.54%.
Neither. Based on ValueRay´s Fundamental Analyses, Henry Schein is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.17 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HSIC is around 68.62 USD . This means that HSIC is currently overvalued and has a potential downside of -7.87%.
Henry Schein has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold HSIC.
- Strong Buy: 3
- Buy: 4
- Hold: 8
- Sell: 0
- Strong Sell: 1
According to our own proprietary Forecast Model, HSIC Henry Schein will be worth about 74.7 in July 2026. The stock is currently trading at 74.48. This means that the stock has a potential upside of +0.31%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 76.4 | 2.5% |
Analysts Target Price | 76.4 | 2.5% |
ValueRay Target Price | 74.7 | 0.3% |